Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Guardant Health's Enterprise Value is MXN357,170 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-7,856 Mil. Therefore, Guardant Health's EV-to-EBIT ratio for today is -45.46.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Guardant Health's Enterprise Value is MXN357,170 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-7,144 Mil. Therefore, Guardant Health's EV-to-EBITDA ratio for today is -50.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Guardant Health's Enterprise Value is MXN357,170 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN19,739 Mil. Therefore, Guardant Health's EV-to-Revenue ratio for today is 18.09.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Guardant Health's Enterprise Value is MXN357,170 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4,341 Mil. Therefore, Guardant Health's EV-to-FCF ratio for today is -82.27.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Guardant Health (MEX:GH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Guardant Health's current Enterprise Value is MXN357,170 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7,856 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Guardant Health's current Enterprise Value is MXN357,170 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7,144 Mil.
Guardant Health's current Enterprise Value is MXN357,170 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN19,739 Mil.
Guardant Health's current Enterprise Value is MXN357,170 Mil.
Guardant Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3,443 Mil.
Guardant Health's current Enterprise Value is MXN357,170 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,341 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health Enterprise Value Related Terms
Guardant Health Enterprise Value Historical Data
* Premium members only.
The historical data trend for Guardant Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GH vs LH, DGX, MEDP: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Guardant Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Guardant Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Guardant Health's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN357,170 Mil mean?
Guardant Health (MEX:GH) has a Enterprise Value of MXN357,170 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Guardant Health and its competitors.
Is Guardant Health's Enterprise Value too high?
Guardant Health's current Enterprise Value is MXN357,170 Mil. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Enterprise Value compare to LH and DGX?
Guardant Health's Enterprise Value of MXN357,170 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Guardant Health and its competitors. Guardant Health's current Enterprise Value is MXN357,170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,048.04, compared to a current price of MXN2,590.00 — trading 147.1% above its estimated fair value. The current Enterprise Value is MXN357,170 Mil. Guardant Health's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current Enterprise Value is MXN357,170 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 147.1% above its estimated GF Value™ of MXN1,048.04.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
Enterprise Value: MXN357,170 Mil
GF Value™: MXN1,048.04 vs. price of MXN2,590.00 (147.1% above fair value)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
